<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="222b31d9-7cb1-4d2d-a36b-1b5652ae148e"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">NystopÂ®</content>
      <br/>Nystatin Topical Powder, USP<br/>
      <content styleCode="bold">Rx Only</content>
      <br/>For topical use only.<br/>Not for ophthalmic use.</title>
   <effectiveTime value="20240111"/>
   <setId root="5bce98a3-2964-4edc-b8da-8a46dafadf5e"/>
   <versionNumber value="104"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
            <name>Bryant Ranch Prepack</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                  <name>Bryant Ranch Prepack</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                        <name>Bryant Ranch Prepack</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="63629-8696"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RELABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="63629-8696"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="512e0fb2-d714-4f66-90f7-f8f927068679"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20220223"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63629-8696" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Nystop</name>
                        <formCode code="C42972" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Nystatin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0574-2008" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="[USP'U]" value="100000"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="BDF1O1C72E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NYSTATIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="BDF1O1C72E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NYSTATIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="15"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63629-8696-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19960816"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA064118" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19960816"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <observationMedia ID="ID_4a221043-a6e5-4cdf-b215-3705613e32b1">
                     <text>Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8abdcc4f-8d35-415a-936c-5a501b6de0ac">
               <id root="12879feb-53ff-4549-97d0-787a500181ec"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Nystatin is a polyene antifungal antibiotic obtained from <content styleCode="italics">Streptomyces nursei. </content>The molecular formula for Nystatin is C<sub>47</sub>H<sub>75</sub>NO<sub>17</sub>. The molecular weight of Nystatin is 926.1.</paragraph>
                  <paragraph>Structural formula:</paragraph>
                  <renderMultiMedia referencedObject="ID_4a221043-a6e5-4cdf-b215-3705613e32b1"/>
                  <paragraph>Nystatin Topical Powder USP is for dermatologic use.</paragraph>
                  <paragraph>Nystatin Topical Powder USP contains 100,000 USP nystatin units per gram dispersed in talc.</paragraph>
               </text>
               <effectiveTime value="20250522"/>
            </section>
         </component>
         <component>
            <section ID="ID_71e186a3-9e74-4c76-9073-9151ff8138df">
               <id root="4eeb7f36-19d3-4d21-ba2b-d5b885aaa3e5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20181114"/>
               <component>
                  <section ID="ID_a0610ccf-3d43-4922-9264-b2a1be53fc1d">
                     <id root="ba31cf87-25f5-4259-a9e0-8b5b24d2cd50"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph>Nystatin is not absorbed from intact skin or mucous membrane.</paragraph>
                     </text>
                     <effectiveTime value="20140917"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_78c2877a-0699-4089-85b1-a81fbd5b97d9">
                     <id root="bf8d780c-8fb1-4d38-8c9e-ff5f3f7763d8"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>Microbiology</title>
                     <text>
                        <paragraph>Nystatin is an antibiotic which is both fungistatic and fungicidal <content styleCode="italics">in vitro </content>against a wide variety of yeasts and yeast-like fungi, including <content styleCode="italics">Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes.</content>
                        </paragraph>
                        <paragraph>Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, <content styleCode="italics">Candida albicans </content>does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of <content styleCode="italics">Candida (C, tropicalis, C. guillier mondi, C. krusei, </content>and <content styleCode="italics">C. stellatoides) </content>become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.</paragraph>
                     </text>
                     <effectiveTime value="20181114"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3e8da09f-8556-45d3-958c-e94317431e5d">
               <id root="d30617e4-005f-4b38-85c7-b512bcf6b047"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Nystatin Topical Powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by <content styleCode="italics">Candida albicans </content>and other susceptible <content styleCode="italics">Candida </content>species.</paragraph>
                  <paragraph>
                     <content styleCode="bold">This preparation is not indicated for systemic, oral, intravaginal or ophthalmic use.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20181114"/>
            </section>
         </component>
         <component>
            <section ID="ID_9c2f6f4e-a10e-4f7b-a104-c3a638c91f87">
               <id root="038def30-6efc-4e2b-ba60-b3fa75613d0d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Nystatin Topical Powder is contraindicated in patients with a history of hypersensitivity to <content styleCode="bold">any </content>of its components.</paragraph>
               </text>
               <effectiveTime value="20140917"/>
            </section>
         </component>
         <component>
            <section ID="ID_a6836717-7f71-4919-aa8b-6a8ac93c5fb0">
               <id root="6637748b-b5be-46d5-a8d5-51df06786307"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20181114"/>
               <component>
                  <section ID="gen">
                     <id root="4db591fc-becc-4e5c-8c75-b5e7268740f6"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Nystatin Topical Powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.</content>
                        </paragraph>
                        <paragraph>If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.</paragraph>
                     </text>
                     <effectiveTime value="20181114"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e016f984-54cf-4a1c-a61b-9051bede5742">
                     <id root="8dad1efc-4904-413f-9151-685659c793b2"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>INFORMATION FOR THE PATIENT</title>
                     <text>
                        <paragraph>Patients using this medication should receive the following information and instructions:</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.</item>
                           <item>
                              <caption>2.</caption>Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.</item>
                           <item>
                              <caption>3.</caption>If symptoms of irritation develop, the patient should be advised to notify the physician promptly.</item>
                        </list>
                     </text>
                     <effectiveTime value="20140917"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8895aeb6-8236-4272-9d03-0a37e4e6da47">
                     <id root="026a11df-957d-48c9-986a-89cf7d384344"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph>If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.</paragraph>
                     </text>
                     <effectiveTime value="20140917"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_16bd51ee-baf9-4a24-b7a3-413fb402618d">
                     <id root="6d35efaa-ee2c-4595-8c11-f6ba0795bf2c"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.</paragraph>
                     </text>
                     <effectiveTime value="20140917"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_223c7fb8-561e-43bf-a42d-6c281a026c08">
                     <id root="3ac8a527-50f1-474c-a76d-3d5b7317aca3"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy:</title>
                     <effectiveTime value="20181114"/>
                     <component>
                        <section ID="ID_87195f97-1e3e-470b-a824-1e07764cc9ad">
                           <id root="d551e3c4-393e-42ba-b265-19cd7a54dab7"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>Teratogenic Effects</title>
                           <text>
                              <paragraph>Category C. Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.</paragraph>
                           </text>
                           <effectiveTime value="20181114"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_695335f3-0a26-4345-9f73-d4dc6661c9d8">
                     <id root="91fcafc0-34f2-427c-ad5e-b9c76e6a36bd"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20140917"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b30a7e65-ac16-47ab-846e-8e916f5fad8c">
                     <id root="5767a985-7309-4fe4-8303-71b28c1a2019"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>).</paragraph>
                     </text>
                     <effectiveTime value="20140917"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_16ddf438-bf73-4d1e-bb16-a26367b41359">
               <id root="05fad4b4-af23-439a-828a-bf898f8bf429"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The frequency of adverse events reported in patients using nystatin topical preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See <content styleCode="bold">PRECAUTIONS: General</content>.)</paragraph>
               </text>
               <effectiveTime value="20140917"/>
            </section>
         </component>
         <component>
            <section ID="dosage">
               <id root="83169c8f-8014-4249-bd72-e16480e801ba"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Very moist lesions are best treated with the topical dusting powder.</paragraph>
               </text>
               <effectiveTime value="20140917"/>
               <component>
                  <section ID="ID_02eddb0a-f3a1-4c40-80e1-c91d1080ef0b">
                     <id root="f161df8c-549b-482e-9065-8ba49c3665e9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Adults and Pediatric Patients (Neonates and Older):</title>
                     <text>
                        <paragraph>Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by <content styleCode="italics">Candida </content>species, the powder should be dusted on the feet, as well as, in all foot wear.</paragraph>
                     </text>
                     <effectiveTime value="20140917"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ab0b9452-c6e8-46f8-a302-066d0a11af32">
               <id root="a3d7800a-eee7-4b51-ac86-ed58ac13d1a7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Nystop<sup>Â®</sup> Nystatin Topical Powder USP is supplied as 100,000 units nystatin per gram in 15 g plastic squeeze bottles.</paragraph>
                  <paragraph>(NDC 63629-8696-1)</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content>STORAGE</content>
                     </content>
                  </paragraph>
                  <paragraph>Store at controlled room temperature 15Â°-30Â°C (59Â°-86Â°F); avoid excessive heat (40Â°C; 104Â°F).</paragraph>
                  <paragraph>Repackaged/Relabeled by:<br/>Bryant Ranch Prepack, Inc.<br/>Burbank, CA 91504</paragraph>
               </text>
               <effectiveTime value="20240111"/>
            </section>
         </component>
         <component>
            <section ID="ID_f6899aa2-a569-4332-b166-20a84460f222">
               <id root="d12321d0-bac1-4c3f-91ab-5b3f3dd55e89"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured By Perrigo</paragraph>
                  <paragraph>Minneapolis, MN 55427</paragraph>
                  <paragraph>2122653</paragraph>
                  <paragraph>(09-12)</paragraph>
               </text>
               <effectiveTime value="20250522"/>
            </section>
         </component>
         <component>
            <section>
               <id root="17a5c298-57a2-4859-8d27-afec90efdde9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>Nystatin 100000 unit/gram Powder, #15</paragraph>
                  <renderMultiMedia referencedObject="mm63629"/>
               </text>
               <effectiveTime value="20250522"/>
               <component>
                  <observationMedia ID="mm63629">
                     <text>Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl636298696.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>